<DOC>
	<DOCNO>NCT00389675</DOCNO>
	<brief_summary>This double-blind , active-controlled , long-term study new experimental drug call darusentan . Darusentan currently approve United States Food Drug Administration ( FDA ) , mean doctor prescribe drug . The purpose study evaluate long-term safety darusentan ( optimize dose ) compare active control , administer orally .</brief_summary>
	<brief_title>DORADO-AC-EX - A Long-Term Safety Extension Study Phase 3 DORADOC-AC Study ( Protocol DAR-312 ) Darusentan Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<mesh_term>LU 135252</mesh_term>
	<criteria>SELECTED INCLUSION CRITERIA : 1 . Subjects must competent provide write informed consent ; 2 . Subjects must complete Maintenance Period DAR312 study . SELECTED EXCLUSION CRITERIA : 1 . Subjects discontinue treatment study drug prior end Maintenance Period DAR312 due study drugrelated AE ; 2 . Subjects experience study drugrelated serious adverse event ( SAE ) DAR312 study .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>